Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial

NCATS Open Data2024-04-26 更新2026-08-08 收录

新冠疫苗加强针免疫原性评估

二价疫苗安全性分析

数据链接：

https://doi.org/10.1016/S1473-3099(24)00077-X 数据链接链接失效反馈

官方服务：

资源简介：

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial

创建时间：

2024-03-06

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial

资源简介：

相关数据集